Relay Therapeutics, Inc. (RLAY)
NASDAQ: RLAY · Real-Time Price · USD
18.84
-0.35 (-1.82%)
Sep 18, 2026, 4:00 PM EDT - Market closed
Relay Therapeutics Stock Forecast
Stock Price Forecast
According to 14 analysts polled by S&P Global, Relay Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $27.08. The average 1-year stock price forecast is 43.74% higher than the current stock price, while the lowest is $20 (+6.16%) and the highest is $32 (+69.85%).
Price Target: $27.08 (+43.74%)
Analyst Consensus: Strong Buy
Price Target
Chart* Price targets were last updated on Aug 20, 2026.
Analyst Ratings
The average analyst rating for Relay Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 10 | 11 | 10 | 11 | 11 |
| Buy | 2 | 2 | 2 | 2 | 3 | 3 |
| Hold | 0 | 1 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 13 | 13 | 12 | 14 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $28 → $29 | Buy | Reiterates | $28 → $29 | +53.93% | Aug 20, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Maintains $28 → $31 | Buy | Maintains | $28 → $31 | +64.54% | Aug 14, 2026 |
| Citizens JMP | Citizens JMP | Buy Maintains $21 → $26 | Buy | Maintains | $21 → $26 | +38.00% | Aug 10, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $29 | Buy | Maintains | $29 | +53.93% | Aug 7, 2026 |
| JonesTrading | JonesTrading | Buy Maintains $20 | Buy | Maintains | $20 | +6.16% | Aug 7, 2026 |
Financial Forecast
Revenue This Year
10.53M
from 15.36M
Decreased by -31.41%
Revenue Next Year
16.53M
from 10.53M
Increased by 56.99%
EPS This Year
-1.62
from -1.61
EPS Next Year
-1.64
from -1.62
EPS and Forward PE are based on non-GAAP adjusted numbers.